NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $5.22 +0.02 (+0.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.16▼$5.3250-Day Range$4.04▼$5.9452-Week Range$1.18▼$9.39Volume331,791 shsAverage Volume1.51 million shsMarket Capitalization$596.49 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Applied Therapeutics alerts: Email Address Applied Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.7% Upside$11.00 Price TargetShort InterestBearish7.96% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.32Based on 3 Articles This WeekInsider TradingSelling Shares$1.07 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector188th out of 936 stocksPharmaceutical Preparations Industry79th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.96% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 43.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 3.0 News and Social Media Coverage News SentimentApplied Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Applied Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for APLT on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows6 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,066,861.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Applied Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Applied Therapeutics Stock (NASDAQ:APLT)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More APLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLT Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comApplied Therapeutics (NASDAQ:APLT) Given Outperform Rating at Royal Bank of CanadaJuly 16, 2024 | americanbankingnews.comShort Interest in Applied Therapeutics, Inc. (NASDAQ:APLT) Expands By 9.9%July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 1, 2024 | globenewswire.comApplied Therapeutics Added to Russell 3000® IndexMay 28, 2024 | seekingalpha.comApplied Therapeutics: Navigating Challenges In ARI Development For Rare DiseasesMay 10, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...May 9, 2024 | investorplace.comAPLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comApplied Therapeutics GAAP EPS of -$0.67 misses by $0.51July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | globenewswire.comApplied Therapeutics Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comApplied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 15, 2024 | globenewswire.comApplied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerApril 14, 2024 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)April 6, 2024 | investing.comApplied Therapeutics reveals Phase 3 data on heart drugApril 4, 2024 | finance.yahoo.comApplied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)April 1, 2024 | benzinga.comFDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare DiseaseApril 1, 2024 | benzinga.comWhy Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketSee More Headlines Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+111.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net MarginsN/A Pretax Margin-1,198.47% Return on Equity-1,497.37% Return on Assets-176.54% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$9.99 million Price / Sales59.37 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-25.95Miscellaneous Outstanding Shares114,270,000Free Float104,440,000Market Cap$593.06 million OptionableOptionable Beta1.99 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Shoshana Shendelman Ph.D. (Age 45)Chair of the Board of Directors, Founder, President, CEO & Secretary Comp: $946.08kMr. Les D. Funtleyder (Age 53)CFO, Principal Financial Officer & Independent Director Comp: $48.75kDr. Riccardo Perfetti M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $860.76kMr. Constantine Chinoporos (Age 58)COO & Chief Business Officer Ms. Catherine Thorpe (Age 60)Chief Accounting Officer Mr. Corwin Dale Hooks (Age 57)Chief Commercial Officer More ExecutivesKey CompetitorsAvid BioservicesNASDAQ:CDMOG1 TherapeuticsNASDAQ:GTHXRigel PharmaceuticalsNASDAQ:RIGLPuma BiotechnologyNASDAQ:PBYIJanux TherapeuticsNASDAQ:JANXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 283,793 shares on 7/26/2024Ownership: 0.248%Hennion & Walsh Asset Management Inc.Bought 197,042 shares on 7/20/2024Ownership: 0.172%SG Americas Securities LLCBought 18,567 shares on 7/12/2024Ownership: 0.016%Shoshana ShendelmanSold 61,795 sharesTotal: $266,954.40 ($4.32/share)Riccardo PerfettiSold 22,003 sharesTotal: $95,052.96 ($4.32/share)View All Insider TransactionsView All Institutional Transactions APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $3.35 at the beginning of 2024. Since then, APLT stock has increased by 55.8% and is now trading at $5.22. View the best growth stocks for 2024 here. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.09. The business earned $0.19 million during the quarter, compared to the consensus estimate of $10 million. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Applied Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.25%), Hennion & Walsh Asset Management Inc. (0.17%), SG Americas Securities LLC (0.02%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder, Stacy J Kanter and Chids Mahadevan. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA) and Verizon Communications (VZ). This page (NASDAQ:APLT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
